Excelsior Biopharma Total Liabilities

Latest as of June 2026: NT$728.80 Million TWD ≈ $22.96 Million USD

Excelsior Biopharma total liabilities. Based on the latest financial reports, Excelsior Biopharma (6496) has total liabilities worth NT$728.80 Million TWD (≈ $22.96 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Excelsior Biopharma liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Excelsior Biopharma (2017–2025)

Total liabilities of Excelsior Biopharma from 2017 to 2025. This chart illustrates how Excelsior Biopharma's total liabilities have evolved over time, based on quarterly financial data.

Excelsior Biopharma Competitors by Total Liabilities

The table below lists competitors of Excelsior Biopharma ranked by their total liabilities.

Company	Country	Total Liabilities
Horizon Space Acquisition II Corp. Ordinary share NASDAQ:HSPT	USA	$39.35 Million
Atlantaa Limited NSE:ATLANTAA	India	Rs3.52 Billion
HY Electronic Cayman Ltd TW:6573	Taiwan	NT$915.91 Million
OUTLOOK THERAPEUTICS INC NASDAQ:OTLK	USA	$50.77 Trillion
Citigold Corporation Ltd AU:CTO	Australia	AU$21.77 Million
Nasus Pharma Ltd. NYSE MKT:NSRX	USA	$2.24 Million
SWISS PROPERTIES INV.100 F:SR1	Germany	€454.08 Million
Dr Peng Telecom and Media Group Co Ltd SHG:600804	China	CN¥7.58 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Excelsior Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Excelsior Biopharma asset portfolio.

Liquidity & Leverage Metrics

Excelsior Biopharma Total Liabilities Ratios Explained

Excelsior Biopharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.51	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Excelsior Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Excelsior Biopharma (2017–2025)

The table below shows the annual total liabilities of Excelsior Biopharma from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$679.78 Million ≈ $21.42 Million	+15.83%
2024-12-31	NT$586.89 Million ≈ $18.49 Million	+24.11%
2023-12-31	NT$472.87 Million ≈ $14.90 Million	-6.83%
2022-12-31	NT$507.53 Million ≈ $15.99 Million	-16.65%
2021-12-31	NT$608.90 Million ≈ $19.18 Million	-1.34%
2020-12-31	NT$617.15 Million ≈ $19.44 Million	+152.87%
2019-12-31	NT$244.06 Million ≈ $7.69 Million	-9.90%
2018-12-31	NT$270.88 Million ≈ $8.53 Million	-20.18%
2017-12-31	NT$339.37 Million ≈ $10.69 Million	--

About Excelsior Biopharma

TWO:6496 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$33.97 Million

NT$1.08 Billion TWD

Market Cap Rank

#23125 Global

#1448 in Taiwan

Share Price

NT$23.20

Change (1 day)

+0.87%

52-Week Range

NT$22.85 - NT$30.10

All Time High

NT$150.00